Wanda Biopharmaceuticals' trading volume on February 23rd was $398 million, a 763.89% increase compared to the previous trading day.

2026-02-24 04:27:20

On February 23, 2026, Wanda Biopharmaceuticals (VNDA) had a trading volume of $398 million, ranking 310th among U.S. stocks that day, with a 763.89% increase from the previous day. The trading volume was 47.6285 million shares.

Wanda Biopharmaceuticals (VNDA) rose 41.49% on February 23, 2026, closing at $8.15. The stock increased by 33.83% over the past five trading days, up 8.09% for the entire month of February, down 7.60% year-to-date, and up 83.97% over the past 52 weeks.

*If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies to companies listed for less than 1 month or fewer than 5 trading days).

Wanda Biopharmaceuticals (VNDA)	Trading Volume / USD	Change from Previous Day	Volume
February 23, 2026	$398 million	763.89%	47.6285 million
February 20, 2026	$46.0684 million	488.86%	6.2105 million
February 19, 2026	$7.8233 million	13.26%	1.2911 million
February 18, 2026	$6.9071 million	-36.27%	1.1395 million
February 17, 2026	$10.8373 million	37.70%	1.7637 million

On February 23, 2026, HC Wainwright & Co. maintained a “Buy” rating for Wanda Biopharmaceuticals, with a target price of $24.

Vanda Pharmaceuticals Inc. was incorporated in Delaware in 2002. The company is a leading global biopharmaceutical firm focused on developing and commercializing innovative therapies to address high unmet medical needs and improve patients’ lives. The company strives to advance new approaches by responsibly innovating to bring important new drugs to market. It is committed to using science-supported technologies, including genetics and genomics, in drug discovery, clinical trials, and product commercialization.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.